Regenxbio Rises After Duchenne Update And Sarepta Safety Scare

Encouraging results in younger children with Duchenne is keeping Regenxbio on track for a potential mid-2026 filing for its gene therapy, RGX-202.

Regenxbio
• Source: Alamy

New Phase I/II data from its Duchenne gene therapy candidate, RGX-202, have boosted Regenxbio, just as new concerns emerged about the safety of Sarepta’s established gene therapy, Elevidys (delandistrogene moxeparvovec).

Key Takeaways
  • Two more children have shown raised microdystrophin levels in RGX-202’s Phase I/II study.

Regenxbio presented new data from two more young children who received RGX-202 in the Phase I/II AFFINITY DUCHENNE study at...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Clinical Trials

UCB Follows Fellow European Pharmas With Major US Investment

 
• By 

The Belgian drugmaker is boosting its biologics capacity over the pond.

In Brief: Starton Moves Low-Dose Lenalidomide To Phase IIa For Multiple Myeloma

 

Study to add to safety and tolerability data for infused formulation and may help identify optimal dose for future pivotal trial.

Sanofi Revels In More Positive Rilzabrutinib Data

 
• By 

The oral BTK inhibitor impresses in a Phase II trial for IgG4-related disease.

How AstraZeneca Aims To Stay Ahead In Lupus As New Competition Looms

 

The company has established the efficacy of its biologic Saphenlo in systemic lupus erythematosus but is now investing across modalities to stay ahead of rivals.

More from Advanced Therapies